Cara Therapeutics, Inc. - Common Stock (CARA)
Frequently Asked Questions About Cara Therapeutics, Inc. - Common Stock (CARA)
Has Cara Therapeutics received any regulatory approvals?
Yes, Cara Therapeutics has received regulatory approval from the U.S. Food and Drug Administration (FDA) for its drug candidate, KORSUVA (difelikefalin), for the treatment of pruritus in adults undergoing hemodialysis. This approval marks a significant milestone in bringing effective treatment to patients suffering from severe itch associated with dialysis.
How does Cara Therapeutics approach drug development?
Cara Therapeutics employs a rigorous drug development process that includes preclinical testing, clinical trials, and regulatory submissions. Their approach focuses on leveraging innovative science to identify new therapeutic targets, followed by comprehensive safety and efficacy evaluations to ensure that their products are both effective and safe for patients.
How does Cara Therapeutics communicate with investors?
Cara Therapeutics communicates with investors through regular updates, conference calls, and SEC filings. The company prioritizes transparency and provides insights into its research and development progress, financial performance, and strategic initiatives, ensuring that shareholders are well-informed about its activities.
How does Cara Therapeutics contribute to community engagement?
Cara Therapeutics contributes to community engagement through various initiatives, including partnerships with local organizations, support for health awareness campaigns, and involvement in educational efforts around chronic pain and itch management. The company emphasizes corporate responsibility and strives to positively impact the communities in which it operates.
How does Cara Therapeutics ensure patient safety in drug development?
Cara Therapeutics prioritizes patient safety throughout its drug development process by adhering to stringent regulatory guidelines and conducting comprehensive preclinical and clinical trials. They engage in thorough monitoring of trial participants and implement rigorous risk management strategies to identify and mitigate any potential safety concerns.
What are the future prospects for Cara Therapeutics?
The future prospects for Cara Therapeutics appear promising, given the company's innovative pipeline and strategic focus on unmet medical needs in pain and itch management. Continued advancement in clinical programs, coupled with potential regulatory approvals and market expansions, positions the company for growth in the evolving biopharmaceutical landscape.
What clinical trials are currently active at Cara Therapeutics?
Cara Therapeutics is actively conducting several clinical trials aimed at evaluating the safety and efficacy of its drug candidates in various pain and pruritus indications. These trials are part of a robust pipeline that seeks to advance the company’s research into both novel and existing therapies for unmet medical needs.
What collaborations or partnerships does Cara Therapeutics have?
Cara Therapeutics has established several collaborations with key industry partners, including pharmaceutical companies and academic institutions. These partnerships aim to enhance the development and commercialization of its therapeutic pipeline while leveraging additional expertise and resources in the research and clinical development processes.
What does Cara Therapeutics, Inc. do?
Cara Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing innovative treatments for patients suffering from pain and pruritus (itch). The company utilizes its proprietary technology platform to discover and develop a new class of therapeutics targeting the body’s immune and nervous systems.
What is the financial status of Cara Therapeutics?
As of the most recent financial reports, Cara Therapeutics has demonstrated substantial growth in its revenue streams from product sales and partnerships. The company has strategically managed its resources to support ongoing clinical trials and commercialization efforts, while also evaluating new funding opportunities to enhance its market position.
What is the lead drug candidate of Cara Therapeutics?
Cara Therapeutics’ lead drug candidate is difelikefalin, a first-in-class kappa opioid receptor agonist. Difelikefalin is being developed for the treatment of moderate to severe pruritus in patients with chronic kidney disease on dialysis, as well as for postoperative pain management, with positive Phase 3 trial results supporting its efficacy and safety.
What is the mission of Cara Therapeutics?
The mission of Cara Therapeutics is to improve the quality of life for patients with chronic pain and itch by developing new and effective therapies. The company aims to address unmet medical needs by bringing groundbreaking solutions to the market, ensuring safety and efficacy in their treatment options.
What is the potential market for Cara Therapeutics' products?
The potential market for Cara Therapeutics' products is considerable, particularly in the areas of chronic pain and pruritus management. The prevalence of these conditions among diverse patient populations presents significant commercial opportunities, with a growing demand for effective and safer therapeutic options that address the limitations of current treatments.
What is the ticker symbol for Cara Therapeutics?
The ticker symbol for Cara Therapeutics on the Nasdaq stock exchange is CARA. Investors use this symbol to trade the company’s common stock, and it reflects Cara's public listing and operational transparency.
What research and development facilities does Cara Therapeutics utilize?
Cara Therapeutics utilizes state-of-the-art research and development facilities equipped with advanced technology and laboratories designed for the discovery and testing of new drugs. Collaborations with academic institutions and industry partners further enhance their research capabilities and accelerate development timelines.
What role do kappa opioid receptors play in Cara Therapeutics' research?
Kappa opioid receptors are central to Cara Therapeutics' research as they represent a target for developing pain and itch relief without the addictive properties associated with traditional opioid medications. By selectively activating these receptors, the company aims to create drugs that provide effective analgesia and antipruritic effects while minimizing side effects like respiratory depression.
What types of products does Cara Therapeutics focus on?
Cara Therapeutics focuses on developing treatments for pain management and pruritus, primarily utilizing a unique approach centered on kappa opioid receptor agonists. The lead products in their pipeline aim to provide alternative solutions to conventional therapies while minimizing the risk of opioid addiction and side effects.
Where is Cara Therapeutics headquartered?
Cara Therapeutics is headquartered in Stamford, Connecticut, which serves as a central hub for its research, development, and commercial activities. The location provides access to a robust biopharmaceutical ecosystem and facilitates collaboration with leading research institutions and clinical organizations.
Who are the key executives at Cara Therapeutics?
Key executives at Cara Therapeutics include co-founder and CEO, Eric S. S. E. H. L. L. Y. M. T. H., who brings extensive experience in the biopharmaceutical industry. The management team comprises seasoned professionals with expertise in drug development, operations, and commercialization, driving the company towards its strategic goals.
What is the current price of Cara Therapeutics, Inc. - Common Stock?
The current price of Cara Therapeutics, Inc. - Common Stock is 5.100
When was Cara Therapeutics, Inc. - Common Stock last traded?
The last trade of Cara Therapeutics, Inc. - Common Stock was at 4:00 pm EDT on April 2nd, 2025
What is the market capitalization of Cara Therapeutics, Inc. - Common Stock?
The market capitalization of Cara Therapeutics, Inc. - Common Stock is 279.76M
How many shares of Cara Therapeutics, Inc. - Common Stock are outstanding?
Cara Therapeutics, Inc. - Common Stock has 54.86M shares outstanding.